Lantheus Holdings heads into the final week of June with the stock up 5.7% on the week and options positioning flashing one of its most bullish readings of the past year.
The clearest signal right now is in options. The put/call ratio dropped sharply to 0.55 on Friday, nearly four standard deviations below its 20-day average of 0.64. That is a near-extreme reading — close to the 52-week low of 0.31 — and it suggests call demand has surged relative to recent norms. The move stands in contrast to the preceding three weeks, when the PCR sat in a tight band between 0.62 and 0.66, making Friday's print look like a genuine shift rather than noise. Whether that reflects fresh bullish positioning or short-dated hedges rolling off, the directional tilt is unmistakably toward upside participation.
Short interest paints a more nuanced picture. Bears have been rebuilding modestly — SI climbed to 8.9% of free float as of June 25, up about 8% in a single session and roughly 5.5% on the week. That keeps the short base meaningful but not extreme. The borrow market, however, gives shorts no urgency to cover: availability is running near 540% of short interest, well above both tight and normal thresholds, and the cost to borrow is a negligible 0.52%. Nothing in the lending data suggests a squeeze setup. The short score has ticked up to 58.5 from 56.5 over the past two weeks, consistent with that modest rebuild, but the score remains far from distressed territory.
The Street has been steadily raising its view on Lantheus all year. Mizuho lifted its target to $115 in late May, maintaining an Outperform, after having already raised twice in the prior quarter. Truist and Citizens followed a similar cadence after Q1 results — all three now sit at $115. The consensus mean of $105 has been overtaken by the current price of $109.80, which is notable: the stock has outrun the average target without triggering any visible pushback from covering analysts. On valuation, the PE is running near 18x and EV/EBITDA near 12.5x, both having eased slightly over the past 30 days even as the price climbed — a reflection of earnings estimates being revised upward. Factor scores support the constructive tone: EPS surprise ranks in the 85th percentile, and 90-day EPS momentum scores a 70, though the short score rank sits at just the 16th percentile, which broadly aligns with the manageable short base.
Institutional ownership offers supporting texture. American Century added over one million shares in the most recent reporting period, a material move relative to their prior position. FMR (Fidelity) added roughly 303,000 shares. BlackRock holds the largest block at 12.6% of shares and nudged its position higher. The dominant direction across the top holders is accumulation, even if the scale of individual moves is incremental.
Lantheus reported Q1 results on May 7 with the stock jumping 8% the next day and extending to a 12% gain over the following week — the prior note on momentum and growth appears well-founded by that print. The next earnings date is August 6, and the bull-bear debate going in centres on whether PYLARIFY's transition to its TruVu formulation sustains volume and whether pipeline diagnostics tied to Alzheimer's therapeutics see a meaningful commercial inflection. The bear case flags cautious full-year guidance and pipeline dependency. With the stock now above consensus targets and the PCR hitting a year-low extreme on Friday, the dynamic heading into August will be whether that call-heavy positioning reflects genuine conviction or simply a momentum chase that has run ahead of the fundamental setup.
See the live data behind this article on ORTEX.
Open LNTH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
